For many living with Long Covid, the most grueling part of the illness isn’t just the crushing fatigue or the “brain fog” that makes a simple conversation feel like a puzzle. This proves the exhausting fight to get the medication they need. For years, patients and physicians in Germany have operated in a medical gray zone, relying on “off-label” prescriptions—drugs approved for one condition but used to treat another—often at the patient’s own expense and the doctor’s own legal risk.
This precarious balance is shifting. Following a 2023 round table convened by then-Health Minister Karl Lauterbach, Germany is introducing an official off-label list for Long and Post-Covid treatments. Approved in April by the Federal Joint Committee (G-BA) after three years of rigorous evaluation by the Federal Institute for Drugs and Medical Devices (BfArM), the list provides a critical bridge to care for those whose lives have been sidelined by a virus that refuses to leave.
As a physician, I have seen how the lack of standardized guidelines creates a “postcode lottery” of care. When there is no approved cure, doctors often lean on clinical experience and small-scale studies. However, prescribing off-label typically means the physician assumes full liability if something goes wrong, and insurance providers frequently refuse to cover the costs. To bypass this, some doctors have resorted to documenting psychiatric diagnoses—such as depression—simply to secure insurance reimbursement for medications that were actually being used to treat physical exhaustion or cognitive impairment.
The new G-BA list aims to end this diagnostic dishonesty. By officially recognizing the utility of four specific substances, the government is shifting the liability back to the manufacturers and ensuring that these treatments are accessible via standard health insurance prescriptions.
The High Stakes of Off-Label Prescribing
To understand why a “short list” is a victory, one must understand the bureaucracy of the “label.” When a drug is approved, it is licensed for a specific indication, age group, and dosage. Using it outside these parameters is “off-label.” While Here’s common in medicine—roughly 13% of all prescriptions are off-label—it creates significant hurdles in a highly regulated system like Germany’s.
Without official G-BA approval, insurance companies generally do not cover off-label drugs unless a patient submits a complex individual application. Because the dosing for Long Covid was never part of the original clinical trials for these drugs, physicians were often guessing based on anecdotal evidence, increasing the risk of adverse effects and legal exposure.
The new framework changes the math. For the medications on the approved list, physicians no longer need to provide an “incorrect” diagnosis to get the drug paid for. They now have concrete guidance on application, dosage, and duration of treatment, providing a level of clinical safety that was previously absent.
Breaking Down the Approved Medications
The list is intentionally lean. The G-BA requires “robust evidence” before granting reimbursement, and because the global research on Long Covid is still fragmented, only four agents met the threshold. These include three for symptom management and one for prevention.
| Medication | Original Use | Long/Post-Covid Application | Key Benefit/Note |
|---|---|---|---|
| Ivabradine | Angina pectoris/Heart failure | Tachycardia (rapid heart rate) upon standing | 78% of patients in studies reported symptom improvement. |
| Agomelatine | Severe depression | Exhaustion (common in ME/CFS) | Shown to improve quality of life and fatigue over 12 weeks. |
| Vortioxetine | Adult depression | Cognitive impairment and attention deficits | Improves cognitive effects; currently unavailable on German market. |
| Metformin | Type 2 Diabetes | Prevention for overweight individuals | Must be administered within 3 days of initial infection. |
The inclusion of Metformin is particularly notable as a prophylactic measure. For adults and adolescents over 16 who are overweight, the drug may reduce the risk of developing Long Covid if taken immediately following the initial infection. Meanwhile, the inclusion of Ivabradine offers a lifeline to those suffering from POTS-like symptoms (Postural Orthostatic Tachycardia Syndrome), where the heart rate spikes dangerously upon standing.
The Bureaucratic Trade-off: Germany vs. Austria
Patient advocacy groups have pointed to Austria as a model of efficiency, where an off-label list was implemented by late 2024. However, the German approach, while slower, offers more comprehensive protections. In Austria, only the three largest health insurance funds cover the costs, and physicians continue to carry the legal liability for the prescriptions.
Germany’s three-year wait was the result of a cautious, evidence-based grind. The BfArM expert group spent years scrubbing through thin data to ensure that only medications with a proven benefit were listed. While the delay is frustrating for patients currently suffering, the result is a system where the manufacturer—not the family doctor—holds the risk, and the coverage is universal across statutory health insurance.
The Gap in Care and the Path to 2026
Despite the progress, the list is far from exhaustive. Many clinicians, including Astrid Weber, head of the Long-Covid clinic in Koblenz, have expressed disappointment over the exclusion of Low-Dose Naltrexone (LDN). LDN is widely used off-label to manage inflammation and pain, but because it is expensive—costing patients between 80 and 90 euros per month—the lack of insurance coverage is a significant financial burden.
The exclusion of LDN is not a rejection, but a pause for data. A major Canadian study is currently underway, with results expected in May 2026. If the data proves a significant clinical benefit, LDN could be added to the official list.
In the longer term, the focus is shifting from repurposing old drugs to discovering new ones. The German government has launched the “National Decade against Post-Infectious Diseases,” allocating 500 million euros over ten years to identify the underlying biological mechanisms of these conditions. While the development of a dedicated “cure” can take 10 to 15 years, this investment represents the first systemic attempt to treat post-infectious syndromes as a primary public health priority rather than a medical curiosity.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
The next major milestone for the community will be the publication of the Canadian Naltrexone study in May 2026, which will likely determine the next expansion of the G-BA reimbursement list. Until then, the “short list” serves as a vital, if modest, first step toward legitimizing the struggle of millions.
Do you or a loved one struggle with accessing Long Covid treatments? Share your experience in the comments or share this article to help others navigate the new guidelines.
